Apollomics, Inc.

Apollomics, Inc. (Nasdaq: APLM) is a clinical-stage biopharmaceutical company headquartered in Foster City, California, focused on the discovery and development of oncology therapies designed to be combined with other treatments to harness the immune system and target specific molecular pathways that inhibit cancer. Operating since 2016, Apollomics has a pipeline of nine drug candidates spanning small-molecule targeted drugs and biologics, including late-stage programs such as vebreltinib (Phase 2, NSCLC and solid tumors with cMet dysregulation) and uproleselan (Phase 3 in China for relapsed/refractory AML). The company became publicly traded via a business combination with Maxpro Capital Acquisition Corp. Surfaced as a portfolio company of Qiming and added to the API Evangelist network; as a biopharmaceutical company it publishes no public developer API surface — this profile carries its corporate identity and domain-security posture.

Apollomics, Inc. is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Oncology, Precision Medicine, and Clinical Trials.

Apollomics, Inc.’s developer surface includes support, engineering blog, and 4 more developer resources.

🌐 Visit website 📡 Source on GitHub

15.0/100 emerging ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiopharmaceuticalOncologyPrecision MedicineClinical TrialsDrug DevelopmentHealthcareLife Sciences

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 15.0/100 · emerging

Contract Quality 0.0 / 25

Developer Ergonomics 1.3 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/apollomicsinc: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService

TermsOfService

PrivacyPolicy

PrivacyPolicy

Company 2

The organization behind the API

Website

Website

Blog

Blog

Source (apis.yml)

aid: apollomicsinc
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/apollomicsinc.png
name: Apollomics, Inc.
description: 'Apollomics, Inc. (Nasdaq: APLM) is a clinical-stage biopharmaceutical company headquartered in Foster City,
  California, focused on the discovery and development of oncology therapies designed to be combined with other treatments
  to harness the immune system and target specific molecular pathways that inhibit cancer. Operating since 2016, Apollomics
  has a pipeline of nine drug candidates spanning small-molecule targeted drugs and biologics, including late-stage programs
  such as vebreltinib (Phase 2, NSCLC and solid tumors with cMet dysregulation) and uproleselan (Phase 3 in China for relapsed/refractory
  AML). The company became publicly traded via a business combination with Maxpro Capital Acquisition Corp. Surfaced as a
  portfolio company of Qiming and added to the API Evangelist network; as a biopharmaceutical company it publishes no public
  developer API surface — this profile carries its corporate identity and domain-security posture.'
url: https://raw.githubusercontent.com/api-evangelist/apollomicsinc/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- qiming
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-17'
tags:
- Company
- Biopharmaceutical
- Oncology
- Precision Medicine
- Clinical Trials
- Drug Development
- Healthcare
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/apollomicsinc-domain-security.yml
- type: Website
  url: https://apollomicsinc.com
- type: Support
  url: https://www.apollomicsinc.com/contact/
- type: Blog
  url: https://www.apollomicsinc.com/updates/
- type: TermsOfService
  url: https://www.apollomicsinc.com/terms-of-use/
- type: PrivacyPolicy
  url: https://www.apollomicsinc.com/privacy/
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence